Cargando…
Parafibromin Abnormalities in Ossifying Fibroma
Ossifying fibromas are very rare tumors that are sometimes seen as part of the hyperparathyroidism-jaw tumor syndrome (HPT-JT), which is caused by inactivating mutations of the HRPT2/CDC73 tumor suppressor gene. CDC73 mutations have been identified in a subset of sporadic cases but aberrant expressi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212678/ https://www.ncbi.nlm.nih.gov/pubmed/34159287 http://dx.doi.org/10.1210/jendso/bvab087 |
_version_ | 1783709683765215232 |
---|---|
author | Costa-Guda, Jessica Pandya, Chetanya Strahl, Maya Taik, Patricia Sebra, Robert Chen, Rong Uzilov, Andrew V Arnold, Andrew |
author_facet | Costa-Guda, Jessica Pandya, Chetanya Strahl, Maya Taik, Patricia Sebra, Robert Chen, Rong Uzilov, Andrew V Arnold, Andrew |
author_sort | Costa-Guda, Jessica |
collection | PubMed |
description | Ossifying fibromas are very rare tumors that are sometimes seen as part of the hyperparathyroidism-jaw tumor syndrome (HPT-JT), which is caused by inactivating mutations of the HRPT2/CDC73 tumor suppressor gene. CDC73 mutations have been identified in a subset of sporadic cases but aberrant expression of the encoded protein, parafibromin, has not been demonstrated in ossifying fibroma. We sought to determine if loss of parafibromin regularly contributes to the development of sporadic, nonsyndromic ossifying fibroma. We examined a series of 9 ossifying fibromas, including ossifying, cemento-ossifying, and juvenile active variants, for parafibromin protein expression by immunohistochemistry and for CDC73 sequence abnormalities by Sanger sequencing and/or targeted AmpliSeq panel sequencing. Four ossifying fibromas showed a complete absence of nuclear parafibromin expression; loss of parafibromin expression was coupled with aberrant cytoplasmic parafibromin expression in 1 case. CDC73 mutations were detected in 2 cases with aberrant parafibromin expression. These results provide novel evidence, at the level of protein expression, that loss of the parathyroid CDC73/parafibromin tumor suppressor may play a role in the pathogenesis of a subset of ossifying fibromas. |
format | Online Article Text |
id | pubmed-8212678 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-82126782021-06-21 Parafibromin Abnormalities in Ossifying Fibroma Costa-Guda, Jessica Pandya, Chetanya Strahl, Maya Taik, Patricia Sebra, Robert Chen, Rong Uzilov, Andrew V Arnold, Andrew J Endocr Soc Research Article Ossifying fibromas are very rare tumors that are sometimes seen as part of the hyperparathyroidism-jaw tumor syndrome (HPT-JT), which is caused by inactivating mutations of the HRPT2/CDC73 tumor suppressor gene. CDC73 mutations have been identified in a subset of sporadic cases but aberrant expression of the encoded protein, parafibromin, has not been demonstrated in ossifying fibroma. We sought to determine if loss of parafibromin regularly contributes to the development of sporadic, nonsyndromic ossifying fibroma. We examined a series of 9 ossifying fibromas, including ossifying, cemento-ossifying, and juvenile active variants, for parafibromin protein expression by immunohistochemistry and for CDC73 sequence abnormalities by Sanger sequencing and/or targeted AmpliSeq panel sequencing. Four ossifying fibromas showed a complete absence of nuclear parafibromin expression; loss of parafibromin expression was coupled with aberrant cytoplasmic parafibromin expression in 1 case. CDC73 mutations were detected in 2 cases with aberrant parafibromin expression. These results provide novel evidence, at the level of protein expression, that loss of the parathyroid CDC73/parafibromin tumor suppressor may play a role in the pathogenesis of a subset of ossifying fibromas. Oxford University Press 2021-05-08 /pmc/articles/PMC8212678/ /pubmed/34159287 http://dx.doi.org/10.1210/jendso/bvab087 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Research Article Costa-Guda, Jessica Pandya, Chetanya Strahl, Maya Taik, Patricia Sebra, Robert Chen, Rong Uzilov, Andrew V Arnold, Andrew Parafibromin Abnormalities in Ossifying Fibroma |
title | Parafibromin Abnormalities in Ossifying Fibroma |
title_full | Parafibromin Abnormalities in Ossifying Fibroma |
title_fullStr | Parafibromin Abnormalities in Ossifying Fibroma |
title_full_unstemmed | Parafibromin Abnormalities in Ossifying Fibroma |
title_short | Parafibromin Abnormalities in Ossifying Fibroma |
title_sort | parafibromin abnormalities in ossifying fibroma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212678/ https://www.ncbi.nlm.nih.gov/pubmed/34159287 http://dx.doi.org/10.1210/jendso/bvab087 |
work_keys_str_mv | AT costagudajessica parafibrominabnormalitiesinossifyingfibroma AT pandyachetanya parafibrominabnormalitiesinossifyingfibroma AT strahlmaya parafibrominabnormalitiesinossifyingfibroma AT taikpatricia parafibrominabnormalitiesinossifyingfibroma AT sebrarobert parafibrominabnormalitiesinossifyingfibroma AT chenrong parafibrominabnormalitiesinossifyingfibroma AT uzilovandrewv parafibrominabnormalitiesinossifyingfibroma AT arnoldandrew parafibrominabnormalitiesinossifyingfibroma |